Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Kairos Pharma, LTD. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 11 | 14 | +3 |
| Shares | 601.1K | 968.0K | +366.9K (+61.0%) |
| Value | $341.5K | $371.1K | +$29.6K (+8.7%) |
New holders (7)
Institutions that held Kairos Pharma, LTD. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 309,834 | $118.9K | 0.00% |
| Virtu Financial LLC | 82,092 | $31.0K | 0.00% |
| Jane Street Group, LLC | 33,749 | $12.9K | 0.00% |
| Susquehanna International Group, LLP | 29,292 | $11.2K | 0.00% |
| XTX Topco Ltd | 14,918 | $5.72K | 0.00% |
| UBS Group AG | 6,261 | $2.40K | 0.00% |
| Barclays PLC | 723 | $277 | 0.00% |
Sold out (4)
Institutions that held Kairos Pharma, LTD. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Two Sigma Investments, LP | 39,543 | $22.1K |
| HRT Financial LP | 21,575 | $12.0K |
| Two Sigma Securities, LLC | 16,247 | $9.08K |
| Citigroup Inc | 10 | $6 |